



phi

PHASE
HOLOGRAPHIC
IMAGING

Phase Holographic Imaging Announces Management Changes

Recent technical progress has led the Board of Directors of Phase Holographic Imaging (PHI) to decide to focus resources on the company's clinical product development program. In relation to this, the Board of Directors has, in discussion with CEO Anders Månsson, decided to initiate the search for a new CEO to lead the ambitious development that lies ahead.

Anders will step down immediately and assist with the transition. Ivan Jurkovic, PHI board member and Altium group CFO, will serve as the acting CEO of PHI during the recruitment process. In his current technology developer role, PHI's founding board member and former CEO, Peter Egelberg, will assist in product development and technical matters.

"I was recruited for the CEO position in PHI as an interim assignment. Now, it will be shorter than originally anticipated. Still, I understand the desire of our largest shareholder, Altium, for a more direct level of involvement now that their stake in the company is even larger following the recent rights issue. I wish both Altium and PHI the best of luck going forward", says Anders Månsson.

"We appreciate what Anders has accomplished in this short but transforming period for PHI. With the new capital from the share issue, we will now set a new direction for the company", says Chairman Goran Dubravcic.

About Ivan Jurkovic

Ivan Jurkovic (Board member, born 1984) is an experienced financial executive with experience in the pharmaceutical industry, beverage industry and IT industry. Mr. Jurkovic currently holds the position of Chief Financial Officer at Altium SA. As part of his role at Altium, Mr. Jurkovic is responsible for Altium's financial operations in nine countries and drives the development of financial strategy, risk management and sustainable growth.

This disclosure contains information that Phase Holographic is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 11-02-2025 10:12 CET.

For additional information, please contact:

Goran Dubravcic

E-mail: ir@phiab.com

Web: www.phiab.com – Live cell imaging & analysis

About PHI

Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI's current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the

emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.